Nelfinavir treatment has no effect on risk of cancers
Source: AidsMap.com Treatment with the protease inhibitor nelfinavir (Viracept) is not independently associated with a reduced risk of cancers, US investigators report in a study published in the online edition of the Journal of Acquired Immune Deficiency Syndromes. Nelfinavir was a widely used drug in early antiretroviral regimes. It has since fallen out of favour after [...]
Source: feedproxy.google.com

Study examines burden tiered Part D system places on patients with RA.
MedPage Today (6/4, Fiore) reported that, according to a study published in the June 15 issue of Arthritis Care & Research, “the sickest and poorest Medicare patients” with rheumatoid arthritis (RA) “enrolled themselves in Part D prescription plans that were less generous and had more restrictions than Medicare Advantage plans.” For the study, researchers from [...]
Source: feedproxy.google.com

Stiefel Laboratories Reaps First Fruits Of Barrier Acquisition With Completion Of Pivotal Phase III Clinical Trial For 200 Mg Hyphanox(TM)
Stiefel Laboratories, Inc. announced the completion and analysis of a pivotal phase III clinical trial for Hyphanox(TM) (itraconazole) tablet. The 200 mg itraconazole tablet formulation was developed using the proprietary Meltrex(R) technology. This trial is the largest randomized controlled clinical study in onychomycosis ever undertaken.
Source: www.medicalnewstoday.com

Heaviest Smokers Face Greatest Risk Of Death After Lung Cancer Diagnosis
It's common knowledge that smoking raises risks of lung cancer. And yet researchers haven't known whether continued smoking by lung cancer patients would increase the risk of the cancer's spread. Researchers at West Virginia University studying the relationship between death rates from lung cancer and how much a person smoked have found that smoking intensity in fact predicts how the disease will progress.
Source: www.medicalnewstoday.com

Three In Every One Thousand U.S. Children Diagnosed With Tourette Syndrome
The first-ever national estimate among a nationally representative sample of U.S. children revealed that 3 out of every 1,000 children between the age of 6 and 17 in the United States have been diagnosed with Tourette Syndrome (TS), according to a study by the Centers for Disease Control and Prevention (CDC) released in the Morbidity and Mortality Weekly Report.
Source: www.medicalnewstoday.com

Newer Treatments for Schizophrenia: Benefits and Drawbacks
New treatments for patients with schizophrenia may be on the horizon, according to research presented at the annual meeting of the American Psychiatric Association (APA) in San Francisco.1 While some of these therapies may help treat the negative and cognitive symptoms of schizophrenia, a few are associated with QTc interval prolongation. Although about 70% of patients [...]
Source: feedproxy.google.com

Medicare drug program is confusing and costly
Source: ajc.com Columnist Charles Kraut-hammer and others have extolled the benefits of the Medicare Part D prescription drug benefit for seniors on the basis that competition drives down prices and the program, taken as a whole, is far more efficient than government-run programs. I wonder whether these writers have had any personal experience with the Medicare Part [...]
Source: feedproxy.google.com

ACTEMRA(R) (tocilizumab) Studies To Be Featured At The European League Against Rheumatism (EULAR) Congress
Roche announced that oral and poster presentations highlighting results from the extensive multi-national ACTEMRA(R) (tocilizumab) clinical development program will be presented at the 10th Annual Congress of the European League Against Rheumatism (EULAR), which will take place June 10-13, 2009, in Copenhagen, Denmark. The studies evaluate ACTEMRA, a novel treatment targeting interleukin-6 (IL-6) receptors, in patients with moderately to severely active RA.
Source: www.medicalnewstoday.com

Paclitaxel Poliglumex (OPAXIO(TM)) Added To Cisplatin And Radiation Produces 45% Pathologic Complete Remissions In Patients With Esophageal Cancer
Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) announced that, in a study released from Brown University at the 2009 American Society for Clinical Oncology (ASCO) Annual Meeting, patients with cancer of the lower esophagus had evidence of a high pathological complete response ("CR") rate when given OPAXIO, a biologically enhanced paclitaxel, in addition to cisplatin and full-course radiotherapy. Concurrent chemotherapy with 50.
Source: www.medicalnewstoday.com